INS and Down syndrome: We also found that Ilp2HF bioactivity is impaired by introduction of an “Akita” missense mutation, analogous to mutations previously shown to disrupt post-translational insulin processing in rodents, and in humans with dominant mutant proinsulin syndrome [14], [15].